A Randomized, Double-blind, Multiple-dose, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ACZ885 in Patients With Newly Diagnosed Type-1 Diabetes Mellitus (T1DM).
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2016
At a glance
- Drugs Canakinumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 31 Mar 2011 United Kingdom Clinical Research Network record identified and integrated.
- 22 Mar 2011 New trial record